WO2009099553A3 - Utilisation d’inhibiteur de kinase pour le traitement de l’athérosclérose - Google Patents

Utilisation d’inhibiteur de kinase pour le traitement de l’athérosclérose Download PDF

Info

Publication number
WO2009099553A3
WO2009099553A3 PCT/US2009/000590 US2009000590W WO2009099553A3 WO 2009099553 A3 WO2009099553 A3 WO 2009099553A3 US 2009000590 W US2009000590 W US 2009000590W WO 2009099553 A3 WO2009099553 A3 WO 2009099553A3
Authority
WO
WIPO (PCT)
Prior art keywords
atherosclerosis
treatment
kinase inhibitor
methods
cfms
Prior art date
Application number
PCT/US2009/000590
Other languages
English (en)
Other versions
WO2009099553A2 (fr
Inventor
Zory Shaposhnik
Aldons J. Lusis
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of WO2009099553A2 publication Critical patent/WO2009099553A2/fr
Publication of WO2009099553A3 publication Critical patent/WO2009099553A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des méthodes et des compositions destinées au traitement d’une maladie cardiovasculaire. Selon les méthodes de l'invention, un inhibiteur à petites molécules de cFMS est administré à un patient en une dose efficace pour réduire les signes cliniques d’athérosclérose.
PCT/US2009/000590 2008-02-01 2009-01-30 Utilisation d’inhibiteur de kinase pour le traitement de l’athérosclérose WO2009099553A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2571108P 2008-02-01 2008-02-01
US61/025,711 2008-02-01

Publications (2)

Publication Number Publication Date
WO2009099553A2 WO2009099553A2 (fr) 2009-08-13
WO2009099553A3 true WO2009099553A3 (fr) 2009-12-30

Family

ID=40952598

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/000590 WO2009099553A2 (fr) 2008-02-01 2009-01-30 Utilisation d’inhibiteur de kinase pour le traitement de l’athérosclérose

Country Status (1)

Country Link
WO (1) WO2009099553A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104529911B (zh) * 2014-12-31 2017-06-23 华中农业大学 一种氚标记艾地普林的制备方法
MA46716A (fr) 2016-11-03 2019-09-11 Juno Therapeutics Inc Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
MX2019014288A (es) 2017-06-02 2020-08-03 Juno Therapeutics Inc Articulos de manufactura y metodos relacionados a toxicidad asociada con terapia celular.
US11413310B2 (en) 2017-06-02 2022-08-16 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
CA3067602A1 (fr) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. Modele murin pour evaluer des toxicites associees a des immunotherapies
MA50057A (fr) 2017-09-01 2020-07-08 Juno Therapeutics Inc Expression génique et évaluation d'un risque de développement d'une toxicité suite à une thérapie cellulaire
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
JP2022513689A (ja) 2018-11-30 2022-02-09 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法におけるｂ細胞悪性腫瘍の投与および処置のための方法
KR20210117260A (ko) 2018-11-30 2021-09-28 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법을 사용한 치료방법
WO2021113770A1 (fr) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Procédés liés à la toxicité et à la réponse associées à une thérapie cellulaire pour le traitement de tumeurs malignes des lymphocytes b

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070060577A1 (en) * 2005-09-14 2007-03-15 Player Mark R 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
US20070060577A1 (en) * 2005-09-14 2007-03-15 Player Mark R 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CONWAY ET AL.: "Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.", PNAS, vol. 102, November 2005 (2005-11-01), pages 16078 - 16083 *

Also Published As

Publication number Publication date
WO2009099553A2 (fr) 2009-08-13

Similar Documents

Publication Publication Date Title
WO2009099553A3 (fr) Utilisation d’inhibiteur de kinase pour le traitement de l’athérosclérose
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
WO2008148074A3 (fr) Inhibiteurs de mtor et methodes de traitement mettant en œuvre ces inhibiteurs
WO2010127099A3 (fr) Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
UY31526A1 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
WO2007038459A3 (fr) Composes de carboxyamine et leurs methodes d'utilisation
WO2009065406A3 (fr) Nouveaux composés hydrocarbonés cycliques pour le traitement de maladies
WO2012046030A3 (fr) Inhibiteurs de phosphodiestérase
WO2008076954A3 (fr) Composés hétérocycliques et procédés d'utilisation de ceux-ci
HUE038785T2 (hu) Hagyományos kínai gyógyszerkészítmény szív- és érrendszeri betegségek kezelésére
ECSP088745A (es) Derivados sustituidos de cromanol y su uso
WO2007093880A3 (fr) Nouveaux dérivés d'indolopyrone et leur procédé de préparation
WO2007105015A3 (fr) DÉRIVES D'ACIDE 18ß-GLYCYRRHETINIQUE
WO2011150190A3 (fr) Composés inhibiteurs du virus de l'hépatite c (hcv) et leurs procédés d'utilisation
IL192415A0 (en) Pharmaceutical composition for the treatment of nail diseases
SI2373310T1 (sl) Nove spojine 4- (heterocikloalkil) benzen-1, 3- diola kot inhibitorji tirosinaze, postopek njihove priprave in njihova uporaba v humani medicini in tudi v kozmetiki
WO2006108679A3 (fr) Matieres et compositions pharmaceutiques destinees a inhiber les glyoxalases et utilisation de celles-ci pour lutter contre le cancer
WO2010121675A3 (fr) Thiazolyl-benzimidazoles
ECSP10010711A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
EA201070918A1 (ru) Применение ранолазина для лечения сердечно-сосудистых заболеваний
WO2008130319A3 (fr) Nouveaux composés 805

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09707931

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09707931

Country of ref document: EP

Kind code of ref document: A2